SRRK logo

SRRK
Scholar Rock Holding Corp

2,317
Mkt Cap
$5.74B
Volume
1.19M
52W High
$51.63
52W Low
$27.07
PE Ratio
-14.58
SRRK Fundamentals
Price
$49.96
Prev Close
$49.19
Open
$49.25
50D MA
$45.73
Beta
1.19
Avg. Volume
1.85M
EPS (Annual)
-$3.30
P/B
22.07
Rev/Employee
$0.00
$4,793.94
Loading...
Loading...
News
all
press releases
Scholar Rock (NASDAQ:SRRK) Reaches New 52-Week High - What's Next?
Scholar Rock (NASDAQ:SRRK) Hits New 52-Week High - Time to Buy...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
SG Americas Securities LLC Has $3.72 Million Stock Position in Scholar Rock Holding Corporation $SRRK
SG Americas Securities LLC raised its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 602.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 84,349 shares of the company's stock after buy...
MarketBeat·9d ago
News Placeholder
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.
Zacks·11d ago
News Placeholder
Wedbush Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock
Wedbush raised their price objective on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an "outperform" rating in a research report on Wednesday...
MarketBeat·11d ago
News Placeholder
Scholar Rock (NASDAQ:SRRK) Sets New 12-Month High - Should You Buy?
Scholar Rock (NASDAQ:SRRK) Reaches New 12-Month High - Here's What Happened...
MarketBeat·11d ago
News Placeholder
Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept.
Scholar Rock (NASDAQ:SRRK) said it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration for apitegromab as a treatment for children and adults with spinal...
MarketBeat·11d ago
News Placeholder
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing
Scholar Rock shares jumped 12% after the company resubmitted its Biologics License Application with the FDA for its treatment of Spinal Muscular Atrophy.
Stocktwits·12d ago
News Placeholder
Scholar Rock (NASDAQ:SRRK) Shares Gap Up - Here's Why
Scholar Rock (NASDAQ:SRRK) Shares Gap Up - Still a Buy...
MarketBeat·12d ago
News Placeholder
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance...
Business Wire·12d ago
News Placeholder
E. Ohman J or Asset Management AB Has $721,000 Stake in Scholar Rock Holding Corporation $SRRK
E. Ohman J or Asset Management AB cut its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 76.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,374 shares of the co...
MarketBeat·17d ago
<
1
2
...
>

Latest SRRK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.